Clinical trials: Liraglutide
Type 1 Diabetes Mellitus
Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function
- Trial name
- DIAB-01 (NCT02109315)
- Testing
- Vitamine C, Liraglutide 6 mg
- Where
- Spain
- Sponsor
- Anna Cruceta
Type 1 Diabetes
Liraglutide in Adolescents With Type 1 Diabetes
The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type…
- Trial name
- NCT02516657
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University at Buffalo
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Diabetes, Diabetes Mellitus, Type 2
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic…
- Trial name
- PIONEER 9 (NCT03018028)
- Testing
- Semaglutide, Liraglutide
- Where
- 16 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Diabetes, Diabetes Mellitus, Type 2
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function
This trial is conducted in Europe. The aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.
- Trial name
- NCT01507389
- Testing
- liraglutide
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Saxenda: Underlying Mechanisms and Clinical Outcomes
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
- Trial name
- NCT02944500
- Testing
- liraglutide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Obesity, Weight Loss
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery.
- Conditions
- Obesity, Weight Loss, Bariatric Surgery
- Trial name
- NCT07374445
- Testing
- Liraglutide injection, Diet and exercise guidelines
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cardiovascular Kidney Metabolic Syndrome
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Complex pathophysiological interactions among obesity, metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system lead to poor cardiovascular-kidney-metabolic health (CKMH), which is a major determinant…
- Trial name
- DASH-CKMH (NCT07188545)
- Testing
- Intervention, Active Comparator
- Where
- United States
- Volunteers
- 23,280,000 people
- Sponsor
- Ohio State University
Diabetes Mellitus, Type 2
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: 60 patients…
- Trial name
- NCT03878706
- Where
- Greece
- Volunteers
- 240 people
- Sponsor
- University of Athens
Diabetes Mellitus, Type 2
A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks.
- Trial name
- INTENSIFY (NCT03823339)
- Testing
- Insulin degludec/liraglutide
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Parkinson Disease
Safety and Efficacy of Liraglutide in Parkinson's Disease
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
- Trial name
- NCT02953665
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Cedars-Sinai Medical Center
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 4 (NCT02863419)
- Testing
- semaglutide, liraglutide
- Where
- 108 sites in United States, Croatia and 11 more
- Volunteers
- 711 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Incretin-based Drugs and the Risk of Heart Failure
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure…
- Trial name
- NCT02456428
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,499,650 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes Mellitus
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health…
- Trial name
- NCT03707171
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Third Military Medical University
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmacokinetics in non-diabetic…
- Trial name
- NCT00978393
- Testing
- liraglutide
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2, Prader Willi Syndrome
Liraglutide Use in Prader-Willi Syndrome
Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in…
- Trial name
- NCT01542242
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Vancouver General Hospital
Type 2 Diabetes Mellitus, End-stage Renal Disease
Liraglutide Treatment to Patients With Severe Renal Insufficiency
Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin.
- Trial name
- NCT01394341
- Testing
- Liraglutide
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Bo Feldt-Rasmussen
Obesity
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in…
- Trial name
- NCT02773355
- Testing
- liraglutide 3.0 mg
- Where
- 14 sites in Mexico
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.
- Trial name
- ALFA-1 (NCT02584582)
- Testing
- Liraglutide, Exenatide, Liquid meal test
- Volunteers
- 10 people
- Sponsor
- Hvidovre University Hospital